From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pharmacokinetic data
Protein binding 97%
CAS Number 13838-16-9 YesY
ATC code N01AB04
PubChem CID: 3226
DrugBank DB00228 YesY
ChemSpider 3113 YesY
UNII 91I69L5AY5 YesY
KEGG D00543 YesY
Chemical data
Formula C3H2ClF5O
Molecular mass 184.492 g/mol
 YesY (what is this?)  (verify)

Enflurane (2-chloro-1,1,2,-trifluoroethyl-difluoromethyl ether) is a halogenated ether. Developed by Ross Terrell in 1963, it was first used clinically in 1966. It was increasingly used for inhalational anesthesia during the 1970s and 1980s[1] but is no longer in common use.

Enflurane is a structural isomer of isoflurane. It vaporizes readily, but is a liquid at room temperature.

Physical properties[edit]

Property Value
Boiling point at 1 atm 56.5 °C
MAC 1.68
Vapor pressure at 20 °C 22.9 kPa (172 mm Hg)
Blood:gas partition coefficient 1.9
Oil:gas partition coefficient 98

Side effects[edit]

Clinically, enflurane produces a dose-related depression of myocardial contractility with an associated decrease in myocardial oxygen consumption. Between 2% and 5% of the inhaled dose is oxidised in the liver, producing fluoride ions and difluoromethoxy-difluoroacetic acid. This is significantly higher than the metabolism of its structural isomer isoflurane.

Enflurane also lowers the threshold for seizures, and should especially not be used on people with epilepsy. It is also known to cause malignant hyperthermia.

It relaxes the uterus in pregnant women.

Enflurane and methoxyflurane have a nephrotoxic effect and cause acute renal failure, usually by its nephrotoxic metabolite.[2]


The exact mechanism of the action of general anaesthetics have not been delineated.[3] Enflurane acts as a positive allosteric modulator of the GABAA, glycine, and 5-HT3 receptors,[4][5] and as a negative allosteric modulator of the AMPA, kainate, and NMDA receptors,[5][6][7] as well as of nicotinic acetylcholine receptors.[4]

Occupational safety[edit]

In the workplace, people may be exposed to enflurane by breathing it in as a waste anaesthetic gas, swallowing it, eye contact, or skin contact. The National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) for exposure to waste anaesthetic gas of 2 ppm (15.1 mg/m3) over a 60 minute period. Symptoms of occupational exposure to enflurane include eye irritation, central nervous system depression, analgesia, anesthesia, convulsions, and respiratory depression.[8]


  1. ^ Niedermeyer, Ernst; Silva, F. H. Lopes da (2005). Electroencephalography: Basic Principles, Clinical Applications, and Related Fields. Lippincott Williams & Wilkins. p. 1156. ISBN 978-0-7817-5126-1. 
  2. ^ By G. Edward Morgan, Maged S. Mikhail, Michael J. Murray, C. Philip Larson; Clinical Anaesthesiology third edition,142.
  3. ^ http://www.scientificamerican.com/article/how-does-anesthesia-work/
  4. ^ a b Elaine K. Perry; Heather Ashton; Allan H. Young (2002). Neurochemistry of Consciousness: Neurotransmitters in Mind. John Benjamins Publishing. pp. 154–. ISBN 1-58811-124-5. 
  5. ^ a b Charles J. Cote; Jerrold Lerman; Brian J. Anderson (2013). A Practice of Anesthesia for Infants and Children: Expert Consult - Online and Print. Elsevier Health Sciences. pp. 499–. ISBN 1-4377-2792-1. 
  6. ^ Paul Barash; Bruce F. Cullen; Robert K. Stoelting; Michael Cahalan; Christine M. Stock; Rafael Ortega (7 February 2013). Clinical Anesthesia, 7e: Print + Ebook with Multimedia. Lippincott Williams & Wilkins. pp. 116–. ISBN 978-1-4698-3027-8. 
  7. ^ Lin LH, Chen LL, Harris RA (1993). "Enflurane inhibits NMDA, AMPA, and kainate-induced currents in Xenopus oocytes expressing mouse and human brain mRNA". FASEB J. 7 (5): 479–85. PMID 7681790. 
  8. ^ "CDC - NIOSH Pocket Guide to Chemical Hazards - Enflurane". www.cdc.gov. Retrieved 2015-10-01.